BIIB080 is currently being evaluated in Phase II as a treatment for patients in the early stages of Alzheimer's disease. It is an oligonucleotide targeting the tau protein, which is associated with changes in the brain linked to Alzheimer's disease.
In early stage clinical studies, BIIB080 has shown positive results by reducing tau protein levels in cerebrospinal fluid and improving cognitive functions in patients in the early stages of the disease, according to Biogen.
BREAKING